METTL2B: A Drug Target and Biomarker for Melanoma (G55798)

Target Name: METTL2B

NCBI ID: G55798

METTL2B

METTL2B: A Drug Target and Biomarker for Melanoma

Melanoma is one of the most aggressive forms of skin cancer, with a high incidence rate and a poor prognosis. Despite advances in surgical and radiation treatments, the survival rate for melanoma remains low, and there is a high need for new therapeutic approaches. The METTL2B gene, located on chromosome 6p21.1, has been identified as a potential drug target and biomarker for melanoma.

The METTL2B gene is a non-coding RNA molecule that has been shown to play a role in the regulation of melanoma cell growth and survival. METTL2B has been shown to encode a protein that can inhibit the activity of the oncogene PIK3CA, which promotes the growth and survival of melanoma cells.

In addition to its role in melanoma, METTL2B has also been shown to be involved in other types of cancer. For example, studies have shown that METTL2B is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, METTL2B has been shown to be involved in the regulation of cell apoptosis, which is a natural process that helps cells eliminate damaged or dysfunctional proteins.

Despite its potential as a drug target, METTL2B is not yet a widely recognized biomarker for melanoma. There is a need for new diagnostic tests and therapies that can be used to detect and treat melanoma at an early stage, when treatment is most effective.

One approach that has been explored for the development of new biomarkers for melanoma is the use of artificial intelligence (AI) and machine learning (ML) algorithms to analyze large datasets. These algorithms can be trained to identify patterns and trends in gene expression that are associated with the development and progression of melanoma.

One of the main advantages of using AI and ML to analyze gene expression data is the ability to identify unique and specific patterns that are associated with melanoma. This can help to identify new biomarkers that can be used to diagnose and treat the disease.

In addition to its potential as a drug target and biomarker, METTL2B has also been shown to be involved in the regulation of other biological processes that are important for human health. For example, METTL2B has been shown to play a role in the regulation of cell signaling pathways, which are involved in a wide range of biological processes, including cell growth, differentiation, and inflammation.

Overall, METTL2B is an promising drug target and biomarker for melanoma. Further research is needed to fully understand its role in the development and progression of melanoma, and to develop new diagnostic tests and therapies that can be used to treat this disease.

Protein Name: Methyltransferase 2B, Methylcytidine

Functions: S-adenosyl-L-methionine-dependent methyltransferase that mediates N(3)-methylcytidine modification of residue 32 of the tRNA anticodon loop of tRNA(Thr)(UGU) and tRNA(Arg)(CCU)

The "METTL2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets